



(51) International Patent Classification:

C07K 14/005 (2006.01) A61K 48/00 (2006.01)

C12N 15/86 (2006.01) C12N 7/00 (2006.01)

(21) International Application Number:

PCT/US2023/066865

(22) International Filing Date:

11 May 2023 (11.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/345,144 24 May 2022 (24.05.2022) US

(71) Applicant: KATE THERAPEUTICS, INC. [US/US];
10675 Sorrento Valley Road, Suite 150, San Diego, CA
92121 (US).

(72) Inventors: FIELDEN, Mark; 10675 Sorrento Valley
Road, Suite 150, San Diego, CA 92121 (US). TABEBOR-
DBAR, Mohammadsharif; 10675 Sorrento Valley Road,
Suite 150, San Diego, CA 92121 (US). SESHADRI, Sau-
rav; 10675 Sorrento Valley Road, Suite 150, San Diego,
CA 92121 (US).

(74) Agent: SCHOEN, Adam, M. et al.; Brown Rudnick LLP,
One Financial Center, Boston, MA 02111 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS FOR TREATING XLMTM

(57) Abstract: The present invention provides a novel muscle-tropic viral vector that achieves MTM1 expression in skeletal muscle. Advantageously, by increasing expression of MTM1 in skeletal muscle, the vector of the present allows for administration of a dose of the composition comprising the vector that substantially reduces the exposure of non-target tissues to the composition.